There are currently 295 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Recruiting
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/18/2025
Locations: Research Site, San Francisco, California +78 locations
Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Recruiting
The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. The exercise therapy in this study will be regular home-based walking sessions on a treadmill, and that therapy will be assigned by an exercise physiologist (a medical professional who studies how exercise affects the human body). Some participants in this study will have the assigned exercise therapy, and some participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of California, Los Angeles (Data and Specimen Analysis Only), Los Angeles, California +8 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
Castrate Resistant Prostate Cancer Enhertu Therapy
Recruiting
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Washington DC VAMC, Washington DC, District of Columbia
Conditions: Prostate Cancer Metastatic, Prostate Cancer, CRPC
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Sarah Cannon Research Institute at HealthOne, Denver, Colorado +23 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Recruiting
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Non-Invasive Biomarkers in Prostate Cancer Disease Management
Recruiting
This study is an observational retrospective/ prospective study with diagnosed low/intermediate risk (no-surgery) \& high risk (surgery) prostate cancer that are eligible and willing to undergo standard of care (SOC) assessment, annually along with biopsies, bio-fluid collection. Participants will obtain genomic and histological evaluation on their biopsied samples. Study follows SOC collection with additional body fluid collection (blood, urine). Biopsy/surgery will not require additional sampl... Read More
Gender:
MALE
Ages:
Between 35 years and 85 years
Trial Updated:
04/16/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Prostate Cancer
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Recruiting
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Prostate Cancer, Prostatic Neoplasms
A Study of Mental Health Care in People With Cancer
Recruiting
The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for connecting older adults with depressed mood to mental health services with the Open Door for Cancer (OD-C) approach. We will find out if the OD-C approach is practical and useful for cancer patients who participate in the intervention and for providers who see or treat cancer patients.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Recruiting
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered in the neoadjuvant setting followed by radical prostatectomy and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered in the neoadjuvant setting.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of California San Francisco, San Francisco, California +5 locations
Conditions: Prostate Cancer
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Recruiting
MMR-deficient cancers of any histologic type appear to be very sensitive to PD-1 blockade with pembrolizumab, and similar data are also beginning to emerge for nivolumab and other immune checkpoint inhibitors. Among the MMR-deficient cancers, the best antitumor responses are often associated with high microsatellite instability (MSI-H status), higher tumor mutational burden (TMB), and higher predicted neoantigen load. Prevalence estimates of MMR deficiency across solid tumor types range from 1%... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Prostate Cancer, Recurrent Prostate Cancer
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Recruiting
The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy and to foster receptivity and informed decision-making around cancer clinical trial participation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Mount Sinai Medical Center, Miami Beach, Florida +1 locations
Conditions: Breast Cancer Invasive, Prostate Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: HonorHealth Research Institute, Phoenix, Arizona +26 locations
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc